Ich suche nach...

Department for Internal Medicine III
Haematology and Internal Oncology

Typical blood disorders

Multiple myeloma

Multiple myeloma and associated plasma cell disorders are treated at our outpatient myeloma clinic. Multiple myeloma is currently an incurable disease. However, thanks to advances in treatment in recent years, this disease can be well managed with many new therapies and in many cases can be controlled in the long term.

The proliferation of malignant plasma cells in the bone marrow leads to a significant increase in the production of non-functional proteins (immunoglobulins). This leads directly or indirectly to organ dysfunction such as spontaneous bone fractures, kidney dysfunction, anaemia, increased blood calcium or other less specific symptoms such as confusion, neurological disorders and susceptibility to infection.

  • Treatment options for multiple myeloma have improved significantly in recent years, allowing us to offer each patient a personalised treatment plan. Options range from conventional chemotherapy to modern targeted therapies with new drugs. Cell therapy with autologous or allogeneic stem cell transplantation (foreign or autologous cells) and modern CAR-T cell therapy are also used. We also carry out treatment with bispecific antibodies, i.e. antibodies that can recognise two different target structures on cells at the same time.

    Interdisciplinary cooperation

    In close collaboration with haemato-oncologists (specialists in blood cancer) in private practice and other hospitals, we advise patients on the best individual treatment plan when the disease is first diagnosed and at any time if it returns. Each treatment recommendation is agreed at the multidisciplinary Haematological Tumour Conference. Many of these therapies can be carried out by a haemato-oncologist close to the patient's home.

    In addition to tried and tested standard therapies, we also offer you the opportunity to take part in innovative clinical trials in various treatment situations.

    • Individual, detailed counselling on treatment options for each disease
    • Coordination of a treatment plan in the interdisciplinary Haematological Tumour Board
    • Opportunity to participate in innovative clinical trials with drugs that are not yet available on the open market
    • Close cooperation with haemato-oncology colleagues in the entire region of Eastern Bavaria
    • Intensive patient care before and after autologous or allogeneic stem cell transplantation or CAR-T cell therapy

Contact

Dr. Sabine Gärditz
+49941 944-5510

PD Dr. Daniel Heudobler
ECTU & Outpatient Clinic
+49941 944-14800